Difference between revisions of "Alpha-methylacyl-CoA racemase"
Jump to navigation
Jump to search
Line 7: | Line 7: | ||
==Positive or negative== | ==Positive or negative== | ||
*[[Nephrogenic adenoma]]. | *[[Nephrogenic adenoma]]. | ||
*[[Urothelial carcinoma]] - not useful for differentating ''prostate'' versus ''bladder''. | |||
==Negative== | ==Negative== |
Revision as of 16:38, 11 December 2014
Alpha-methylacyl-CoA racemase, abbreviated AMACR, is a commonly used immunostain in genitourinary pathology.
Positive
Positive or negative
- Nephrogenic adenoma.
- Urothelial carcinoma - not useful for differentating prostate versus bladder.
Negative
See also
References
- ↑ Lloyd, MD.; Yevglevskis, M.; Lee, GL.; Wood, PJ.; Threadgill, MD.; Woodman, TJ. (Apr 2013). "α-Methylacyl-CoA racemase (AMACR): metabolic enzyme, drug metabolizer and cancer marker P504S.". Prog Lipid Res 52 (2): 220-30. doi:10.1016/j.plipres.2013.01.001. PMID 23376124.
- ↑ Molinié, V.; Balaton, A.; Rotman, S.; Mansouri, D.; De Pinieux, I.; Homsi, T.; Guillou, L. (Jun 2006). "Alpha-methyl CoA racemase expression in renal cell carcinomas.". Hum Pathol 37 (6): 698-703. doi:10.1016/j.humpath.2006.01.012. PMID 16733210.